Barclays’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-1,096,869
| Closed | -$52.7M | – | 6581 |
|
|
2020
Q1 | $52.7M | Buy |
1,096,869
+934,426
| +575% | +$43.5M | 0.04% | 302 |
|
|
2019
Q4 | $7.62M | Buy |
162,443
+143,217
| +745% | +$6.33M | ﹤0.01% | 1603 |
|
|
2019
Q3 | $455K | Sell |
19,226
-30,733
| -62% | -$911K | ﹤0.01% | 4316 |
|
|
2019
Q2 | $1.5M | Buy |
49,959
+21,548
| +76% | +$494K | ﹤0.01% | 3241 |
|
|
2019
Q1 | $637K | Buy |
28,411
+6,148
| +28% | +$132K | ﹤0.01% | 3882 |
|
|
2018
Q4 | $405K | Sell |
22,263
-5,479
| -20% | -$86K | ﹤0.01% | 3998 |
|
|
2018
Q3 | $502K | Buy |
27,742
+22,706
| +451% | +$269K | ﹤0.01% | 4278 |
|
|
2018
Q2 | $49K | Sell |
5,036
-2,498
| -33% | -$17.2K | ﹤0.01% | 5660 |
|
|
2018
Q1 | $40K | Buy |
7,534
+1,602
| +27% | +$11.4K | ﹤0.01% | 6064 |
|
|
2017
Q4 | $51K | Sell |
5,932
-4,245
| -42% | -$52.2K | ﹤0.01% | 5752 |
|
|
2017
Q3 | $149K | Buy |
10,177
+3,992
| +65% | +$60.3K | ﹤0.01% | 4648 |
|
|
2017
Q2 | $116K | Buy |
6,185
+2,815
| +84% | +$63.5K | ﹤0.01% | 4804 |
|
|
2017
Q1 | $72K | Sell |
3,370
-109
| -3% | -$2.08K | ﹤0.01% | 5119 |
|
|
2016
Q4 | $52K | Buy |
+3,479
| New | +$47.3K | ﹤0.01% | 5140 |
|
Other funds holding RARX
Barclays's RARX Position: Q2 2020 in Review
Barclays sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 1,096,869 shares — an estimated $52.7M sold.
Barclays first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $52.7M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.
- Barclays reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
- Barclays sold 1,096,869 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $52.7M.
- Barclays first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
- Barclays's Ra Pharmaceuticals, Inc. Common Stock position peaked at $52.7M in Q1 2020.
- 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.
Based on Barclays's 13F filing for Q2 2020, filed 12 Aug 2020.